Current therapies in ovarian cancer
Current therapies in ovarian cancer
复制标题
DOI：
10.1081/cnv-120016409
复制
发表时间：
2003-01-01
影响因子：
2.4
通讯作者：
Runowicz, CD
中科院分区：
文献类型：
--
作者：
Fields, AL;Runowicz, CD
卵巢癌每年影响美国23，400名妇女，造成13，900人死亡。[1]它是美国女性癌症死亡的第五大常见原因，也是妇科恶性肿瘤导致癌症死亡的最常见原因。对于大多数患者，卵巢癌的治疗需要多模式方法，包括手术和化疗。除了少数分化良好的1期疾病患者外，单独手术是不能治愈的。尽管据报道，术后铂类化疗的总体反应率高达80%，但75%以上的晚期卵巢癌患者最终在诊断后5年内死于该病。[2]在过去的十年中，晚期上皮性卵巢癌的治疗发生了变化。具有独特作用机制的新型药物已被纳入一线治疗，目的是影响卵巢癌的总生存率。[6、10、11]
Ovarian cancer affects 23,400 women in the United States annually and is responsible for 13,900 deaths.[1] It is the fifth most common cause of cancer deaths among women in the United States and the most frequent cause of cancer deaths from gynecological malignancies. For the majority of patients, the treatment of ovarian cancer requires a multimodal approach, including surgery and chemotherapy. Surgery alone is not curative, except in a minority of patients presenting with well-differentiated stage 1 disease. Although overall response rates of up to 80% have been reported for postoperative, platinum-based chemotherapy, more than 75% of women with advanced stage ovarian cancer ultimately die of their disease, within five years of diagnosis.[2] The management of advanced epithelial ovarian carcinoma has changed over the past decade. Novel agents with unique mechanisms of action have been incorporated into first-line settings, with the goal to impact the overall survival in ovarian cancer.[6, 10, 11]